Yes, oral amoxicillin is an acceptable and guideline-supported treatment for VRE E. faecalis urinary tract infections when the isolate is susceptible to ampicillin.
Guideline-Based Recommendation
Amoxicillin 500 mg PO every 8 hours is explicitly recommended for uncomplicated urinary tract infections due to VRE when ampicillin susceptibility is confirmed 1. This recommendation appears consistently across the 2022 multidrug-resistant organism treatment guidelines, though it carries a weak recommendation with very low quality evidence (2D).
The FDA drug label for amoxicillin specifically lists Enterococcus faecalis among susceptible organisms for genitourinary tract infections, though it specifies β-lactamase-negative isolates 2. Similarly, ampicillin is FDA-approved for enterococcal genitourinary infections 3.
Key Clinical Reasoning
Why This Works Despite Vancomycin Resistance
The critical insight is that vancomycin resistance and ampicillin resistance are mediated by completely different mechanisms:
- Vancomycin resistance occurs through vanA/vanB operons
- Beta-lactam resistance requires altered penicillin-binding proteins
These mechanisms are independent, which explains why VRE E. faecalis isolates frequently remain ampicillin-susceptible despite vancomycin resistance 4. Recent surveillance data confirms that >90% of VRE E. faecalis isolates remain susceptible to ampicillin 5, and another study showed 82% ampicillin susceptibility 4.
High Urinary Concentrations Overcome Resistance
Even when minimum inhibitory concentrations (MICs) suggest resistance, high urinary concentrations of ampicillin/amoxicillin can overcome elevated MICs and achieve bactericidal activity in the urinary tract 1. This pharmacokinetic advantage is unique to urinary tract infections.
Supporting Clinical Evidence
A retrospective study of 84 patients with ampicillin-resistant AND vancomycin-resistant enterococcal UTIs treated with ampicillin demonstrated:
- 88.1% clinical cure rate
- 86% microbiological eradication 6
These outcomes remained strong even in complicated UTIs with indwelling catheters. A 2026 study showed zero 30-day mortality in patients treated with aminopenicillins for VRE E. faecalis UTIs 4.
Practical Treatment Algorithm
For Uncomplicated VRE E. faecalis Cystitis (Ampicillin-Susceptible):
First-line options:
- Amoxicillin 500 mg PO every 8 hours 1
- Alternative: Nitrofurantoin 100 mg PO every 6 hours 1
- Alternative: Fosfomycin 3 g PO single dose 1
Duration: Minimum 5-7 days for uncomplicated cystitis; continue 48-72 hours beyond symptom resolution 2
Reserve Broader Agents for Specific Situations:
Linezolid 600 mg PO every 12 hours should be reserved for:
- Ampicillin-resistant VRE E. faecalis
- Upper tract infections (pyelonephritis)
- Bacteremic UTIs
- VRE E. faecium (which is typically ampicillin-resistant) 1
Critical Caveats and Pitfalls
Species Matters Enormously
VRE E. faecium behaves completely differently from VRE E. faecalis:
- VRE E. faecium shows <15% ampicillin susceptibility 5
- VRE E. faecalis shows >90% ampicillin susceptibility 5
Always confirm species identification before selecting aminopenicillins.
Distinguish Colonization from Infection
The guidelines emphasize that it is critical to differentiate colonization from true infection before prescribing anti-VRE antimicrobials 1. Unnecessary treatment of asymptomatic bacteriuria with VRE has become a significant antimicrobial stewardship problem 7.
When to Avoid Aminopenicillins
Do not use amoxicillin/ampicillin for:
- Empiric therapy before susceptibility results (resistance rates too variable)
- VRE E. faecium infections
- Confirmed ampicillin-resistant isolates without urinary source
- Serious infections outside the urinary tract (bacteremia, endocarditis, intra-abdominal infections)
Catheter Management
In catheterized patients with VRE UTI, catheter exchange or removal significantly improves outcomes when feasible. Cure rates were 90.5% with catheter exchange/removal versus 87.5% with retention 6.
Antimicrobial Stewardship Perspective
Despite ampicillin/amoxicillin being the most appropriate agent for ampicillin-susceptible VRE E. faecalis UTIs, daptomycin remains the most commonly prescribed agent in clinical practice 4. This represents significant overuse of broad-spectrum agents and highlights an antimicrobial stewardship gap.
The evidence strongly supports using amoxicillin as first-line therapy when susceptibility is confirmed, reserving linezolid and daptomycin for truly resistant or severe infections 7, 4, 8.